| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rosaria Nardello, Fulvio Guccione, Claudia Gliubizzi, Antonio Marino, Mariarita Capizzi, Salvatore Mangan. Resolution of enuresis with aripiprazole in children with psychiatric disorders: two case reports. Journal of medical case reports. vol 15. issue 1. 2021-05-14. PMID:33883037. |
as partial agonist of the dopamine (d2) and serotonin (5-ht1a) receptors, it appears to be effective in reducing mania in patients with bipolar disorder, tics in tourette syndrome, aggression in schizophrenia and autism spectrum disorder. |
2021-05-14 |
2023-08-13 |
Not clear |
| Matheus Libarino-Santos, Ana Catherine Gomes de Santana Santos, Elisangela G Cata-Preta, Thaísa Barros-Santos, Nina Rosa Nunes Brandão, Aurea Lorena Nunes Borges, Renan Santos-Baldaia, André W Hollais, Marilia A Baldaia, Laís F Berro, Eduardo A V Marinho, Roberto Frussa-Filho, Alexandre J Oliveira-Lim. Role of the treatment environment in the effects of aripiprazole on ethanol-induced behavioral sensitization and conditioned place preference in female mice. Drug and alcohol dependence. vol 208. 2021-01-18. PMID:31954952. |
evidence suggests that aripiprazole, a partial dopamine d2 and serotonin 5-ht1a receptor agonist and 5-ht2a receptor antagonist, show significant efficacy in reducing alcohol use. |
2021-01-18 |
2023-08-13 |
mouse |
| Nami Isooka, Ikuko Miyazaki, Ryo Kikuoka, Kouichi Wada, Erika Nakayama, Kotaro Shin, Daichi Yamamoto, Yoshihisa Kitamura, Masato Asanum. Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: Possibly involvement of metallothionein expression in astrocytes. Neurochemistry international. vol 132. 2021-01-07. PMID:31765686. |
rotigotine, an anti-parkinsonian drug, can bind to dopamine and 5-ht1a receptors. |
2021-01-07 |
2023-08-13 |
mouse |
| Chara A Zika, Ioannis Nicolaou, Antonis Gavalas, George V Rekatas, Ekaterini Tani, Vassilis J Demopoulo. Behavioral and antioxidant activity of a tosylbenz[g]indolamine derivative. A proposed better profile for a potential antipsychotic agent. Annals of general hospital psychiatry. vol 3. issue 1. 2020-09-30. PMID:14711381. |
in a previous study we have shown that an indolamine molecule expresses a moderate binding affinity at the dopamine d2 and serotonin 5-ht1a receptors in in vitro competition binding assays. |
2020-09-30 |
2023-08-12 |
rat |
| Lakshmi N Yatham, Eduard Vieta, Roger S McIntyre, Rakesh Jain, Mehul Patel, Willie Earle. Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications. The primary care companion for CNS disorders. vol 22. issue 5. 2020-09-29. PMID:32942346. |
cariprazine, a dopamine d₃-preferring d₃/d₂ receptor partial agonist with serotonin 5-ht1a receptor partial agonist and serotonin 5-ht2a antagonist properties, is approved to treat manic and depressive episodes of bipolar disorder. |
2020-09-29 |
2023-08-13 |
Not clear |
| Shrikant S Kolan, Tommy Lidström, Tomás Mediavilla, Andy Dernstedt, Sofie Degerman, Magnus Hultdin, Karl Björk, Daniel Marcellino, Mattias N E Forsel. Growth-inhibition of cell lines derived from B cell lymphomas through antagonism of serotonin receptor signaling. Scientific reports. vol 9. issue 1. 2020-09-28. PMID:30862884. |
neurotransmitters such as serotonin and dopamine influence activation of b cells and the effects of a selective serotonin 1a receptor (5ht1a) antagonist on growth of a number of b cell-derived lymphoma cell lines were investigated. |
2020-09-28 |
2023-08-13 |
human |
| Lígia Castanheira, Elsa Fernandes, Pedro Levy, Ricardo Coentr. Aripiprazole-induced Hepatitis: A Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 17. issue 4. 2020-09-28. PMID:31671495. |
aripiprazole is an atypical antipsychotic that acts as a partial agonist of dopamine type 2 receptors as well as 5-ht1a receptors. |
2020-09-28 |
2023-08-13 |
Not clear |
| Christoph U Correl. Current Treatment Options and Emerging Agents for Schizophrenia. The Journal of clinical psychiatry. vol 81. issue 3. 2020-09-14. PMID:32297721. |
mechanisms of action that are under investigation include dopamine d3 antagonism/serotonin 5-ht1a partial agonism; combined dopamine, serotonin, and glutamate modulation; phosphodiesterase 10a inhibition; trace amine-associated receptor-1 (taar1) agonism plus 5-ht1a agonism; 5-ht2a inverse agonism; sigma-2/5-ht2a antagonism; d-amino acid oxidase (daao) inhibition; glycine transporter-1 inhibition; vesicular monoamine transporter-2 antagonism; mu opioid antagonism added to olanzapine; and novel long-acting injectable antipsychotic formulations. |
2020-09-14 |
2023-08-13 |
Not clear |
| Betina Elfving, Heidi Kaastrup Müller, Ignasi Oliveras, Tina Becher Østerbøg, Cristobal Rio-Alamos, Ana Sanchez-Gonzalez, Adolf Tobeña, Alberto Fernandez-Teruel, Susana Azna. Differential expression of synaptic markers regulated during neurodevelopment in a rat model of schizophrenia-like behavior. Progress in neuro-psychopharmacology & biological psychiatry. vol 95. 2020-08-28. PMID:31228641. |
we performed a comprehensive characterization of the rha-i/rla-i rats by real-time qpcr and western blotting for 5-ht1a, 5-ht2a, mglu2, dopamine 1 and dopamine 2 receptors (drd1 and drd2), ampa receptor subunits gria1, gria2 and nmda receptor subunits grin1, grin2a and grin2b, as well as pre- and post-synaptic components in pfc and hippocampus (hip). |
2020-08-28 |
2023-08-13 |
rat |
| Munn-Sann Lye, Yin-Yee Tey, Yin-Sim Tor, Aisya Farhana Shahabudin, Normala Ibrahim, King-Hwa Ling, Johnson Stanslas, Su-Peng Loh, Rozita Rosli, Khairul Aiman Lokman, Ibrahim Mohammed Badamasi, Asraa Faris-Aldoghachi, Nurul Asyikin Abdul Raza. Predictors of recurrence of major depressive disorder. PloS one. vol 15. issue 3. 2020-06-23. PMID:32191745. |
for each individual patient, at the time of recruitment as part of a case-control study, information was collected on recent threatening life events, personality and social and occupational functioning, while blood samples were collected to genotype single nucleotide polymorphisms of vitamin d receptor (vdr), zinc transporter-3 (znt3), dopamine transporter-1 (dat1), brain-derived neurotropic factor (bdnf), serotonin receptor 1a (ht1a) and 2a (ht2a) genes. |
2020-06-23 |
2023-08-13 |
Not clear |
| Eduard Vieta, Willie R Earley, Maria V Burgess, Suresh Durgam, Changzheng Chen, Yan Zhong, Ágota Barabássy, György Német. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder. International clinical psychopharmacology. vol 34. issue 2. 2020-02-18. PMID:30531358. |
cariprazine is a d3-preferring dopamine d3/d2 receptor partial agonist and 5-ht1a partial agonist. |
2020-02-18 |
2023-08-13 |
Not clear |
| Christoph U Correll, Steven G Potkin, Yan Zhong, Judit Harsányi, Balázs Szatmári, Willie Earle. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial. The Journal of clinical psychiatry. vol 80. issue 2. 2019-12-23. PMID:30695290. |
cariprazine, a dopamine d₃/d₂ receptor and serotonin 5-ht1a receptor partial agonist, is approved in the united states and europe to treat adults with schizophrenia. |
2019-12-23 |
2023-08-13 |
Not clear |
| Shunsuke Tanahashi, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okad. Corrigendum to "Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission" [Neuropharmacology 62 (2012) 765-774]. Neuropharmacology. vol 148. 2019-11-20. PMID:30733044. |
corrigendum to "dopamine d2 and serotonin 5-ht1a receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission" [neuropharmacology 62 (2012) 765-774]. |
2019-11-20 |
2023-08-13 |
Not clear |
| Marianna Mazza, Giuseppe Marano, Gianandrea Traversi, Valentina Carocci, Benedetta Romano, Luigi Janir. Cariprazine in Bipolar Depression and Mania: State of the Art. CNS & neurological disorders drug targets. vol 17. issue 10. 2019-10-14. PMID:30152291. |
high affinity for d3 dopamine receptors and observed actions on 5ht1a, 5ht2a and alpha 1b receptors differentiate it pharmacologically from other antipsychotics. |
2019-10-14 |
2023-08-13 |
Not clear |
| Darakhshan Jabeen Haleem, Shazia Nawaz, Tabinda Salma. Dopamine and serotonin metabolism associated with morphine reward and its inhibition with buspirone: A study in the rat striatum. Pharmacology, biochemistry, and behavior. vol 170. 2019-03-22. PMID:29782941. |
results suggest that 5-ht1a receptor dependent modulation of dopamine neurotransmission in the cn and nac is involved in the modulation of the rewarding effects of morphine in buspirone co-treated animals. |
2019-03-22 |
2023-08-13 |
rat |
| Asli Ekinci, Okan Ekinc. Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia. Reviews on recent clinical trials. vol 13. issue 1. 2019-01-04. PMID:28828976. |
brexpiprazole acts both as a partial agonist at the serotonin 5-ht1a and dopamine d2 receptors and as an antagonist at the serotonin 5- ht2a and noradrenaline alpha1b and alpha2c receptors, all with similar potency. |
2019-01-04 |
2023-08-13 |
Not clear |
| Gregory T Collins, Charles P Franc. Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys. Experimental and clinical psychopharmacology. vol 26. issue 5. 2018-12-11. PMID:29952618. |
two such drugs, lorcaserin (belviq; a drug with serotonin [5-ht]2c receptor agonist properties) and buspirone (buspar; a drug with 5-ht1a receptor partial agonist and dopamine d3/d4 receptor antagonist properties) can produce modest decreases in cocaine self-administration in rhesus monkeys. |
2018-12-11 |
2023-08-13 |
monkey |
| Hong-Yan Gou, Xue Sun, Fei Li, Zhi-Yuan Wang, Ning Wu, Rui-Bin Su, Bin Cong, Jin L. The antipsychotic-like effects in rodents of YQA31 involve dopamine D3 and 5-HT1A receptor. Pharmacological reports : PR. vol 69. issue 6. 2018-07-27. PMID:29128790. |
the antipsychotic-like effects in rodents of yqa31 involve dopamine d3 and 5-ht1a receptor. |
2018-07-27 |
2023-08-13 |
mouse |
| Hong-Yan Gou, Xue Sun, Fei Li, Zhi-Yuan Wang, Ning Wu, Rui-Bin Su, Bin Cong, Jin L. The antipsychotic-like effects in rodents of YQA31 involve dopamine D3 and 5-HT1A receptor. Pharmacological reports : PR. vol 69. issue 6. 2018-07-27. PMID:29128790. |
we previously reported that yqa31 is a dopamine d3 receptor antagonist with modest 5-ht1a receptor affinity and that it exhibits antipsychotic properties in animal models of schizophrenia. |
2018-07-27 |
2023-08-13 |
mouse |
| Lyang Huh, Bong Ju Le. [Efficacy of low-Dose Aripiprazole to Treat Clozapine-Associated Tardive Dystonia in a Patient with Schizophrenia]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 28. issue 3. 2018-05-25. PMID:28936820. |
aripiprazole is a dopamine d2 receptor partial agonist that exhibits partial agonistic activity against serotonin-1a (5-ht1a) receptors and full antagonistic activity against 5-ht2a receptors. |
2018-05-25 |
2023-08-13 |
Not clear |